Compare TIL & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIL | SACH |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 57.5M |
| IPO Year | 2021 | N/A |
| Metric | TIL | SACH |
|---|---|---|
| Price | $8.04 | $1.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $125.00 | $2.00 |
| AVG Volume (30 Days) | 23.6K | ★ 646.0K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 19.23% |
| EPS Growth | ★ 6.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $145.00 |
| Revenue Next Year | N/A | $6.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $0.90 |
| 52 Week High | $38.50 | $1.45 |
| Indicator | TIL | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 40.96 |
| Support Level | $7.95 | $0.99 |
| Resistance Level | $8.29 | $1.13 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 13.16 | 11.21 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.